Who We Are

The New Jersey Life Sciences Vendors Alliance (NJLSVA) is a coalition of businesses, individuals and academia who provide goods and services to New Jersey’s life sciences companies.

The NJLSVA was founded to educate suppliers on trends in industry procurement and public policy that affects the life sciences industry.

Choose NJ’s RFP Watch

Choose New Jersey’s RFP Watch provides up-to-date information on business opportunities throughout the Garden State at a cost that is affordable for all companies – with a place of business in New Jersey – large and small.

To learn more click here

Medical Innovation

NJIT Assistant Professor Alice Lee Focuses on ‘A Heart Attack in a Petri Dish’

Newark, NJ, July 25, 2017 — In petri dishes in her campus laboratory at New Jersey institute of Technology (NJIT), Assistant Professor Alice Lee is developing colonies of cardiac cells, formed into chambers, that pump and contract like a human heart.

Derived from stem cells, these primitive organs will help her achieve a research milestone:  to observe in microscopic, real-time detail how the heart repairs itself after injury.

Lee must first induce an “attack” by damaging the tiny proto-hearts with a frozen rod, thus mobilizing sequential, cell-based repair crews that clear the injury site of debris, and then in a second phase, recruit materials and tools from the neighboring tissue to mend the damage. Continue reading

VP Joe Biden and Dr. Jill Biden Launch Biden Cancer Initiative; Aims to Make Progress in Cancer Prevention, Detection, Treatment, Care

Dr. Jill Biden and Joe Biden

New York, NY, June 23, 2017 — President Joe Biden and Dr. Jill Biden on June 26 launched the Biden Cancer Initiative, their new venture to continue the fight to make progress in cancer prevention, detection, treatment, and care.

The launch event was highlighted by Vice President and Dr. Biden joining members of the Biden Cancer Initiative Board of Directors for a conversation about the mission of the Initiative, the issues it will address, and the promise of what they hope to accomplish together.

The Biden Cancer Initiative will develop and drive implementation of solutions to accelerate progress in cancer prevention, detection, diagnosis, research and care, and to reduce disparities in cancer outcomes. Continue reading

Rutgers Researcher Receives $4.4 Million Investment to Develop Cancer Therapy

Dr. Scott Kachlany

New Brunswick, NJ, July 20, 2017 Scott Kachlany, Ph.D., a Rutgers School of Dental Medicine researcher, has received a $4.4 million commitment in venture capital to bring a potential therapy for cancer and autoimmune diseases closer to human clinical trials, he announced yesterday.

Dr. Kachlany’s company, Actinobac Biomed Inc., is slated for funding from the California-based Kairos Ventures, which will pay for the final stages of preclinical development before his therapeutic technology, called Leukothera, is tested on humans.

Leukothera is based on Kachlany’s discovery that an oral bacterium, which causes periodontal disease, can produce a protein that can be used to kill leukemia cells in animals. Continue reading

PhRMA ‘Pipeline’ Report: 74 Percent of Medicines in Development Have Potential to Be First-in-Class Treatments

Washington, DC, July 19, 2017 — Seventy-four percent of medicines in clinical development around the world are potentially first-in-class medicines, meaning they use a completely new approach to fighting a disease, according to a new report by The Analysis Group, Inc. commissioned by the Pharmaceutical Research and Manufacturers of America (PhRMA).

“The Biopharmaceutical Pipeline: Innovative Therapies in Clinical Development” report examines the global state of the drug development pipeline and provides insights into new approaches biopharmaceutical researchers are pursuing.

The pipeline report, which updates a previous analysis, highlights new treatment approaches such as cell therapy and gene therapy, as well as DNA or RNA therapeutics and conjugated monoclonal antibodies. Continue reading

PhRMA Releases ‘Research in Your Backyard’ for New Jersey; PhRMA, HINJ and WWFH-NJ Host Discussion Focused on Biopharma Research in Garden State

New Brunswick, NJ, July 18, 2017 — The Pharmaceutical Research and Manufacturers of America (PhRMA) on June 28 released a new report entitled “Research in Your Backyard: Developing Cures, Creating Jobs, Pharmaceutical Clinical Trials in New Jersey,” which finds that 25,127 patients participated in clinical trials around the state in 2013, generating an estimated economic impact of $617 million.

The report was released at an event co-hosted by PhRMA, the HealthCare Institute of New Jersey (HINJ) and We Work for Health New Jersey (WWFH-NJ) that was held at the Rutgers Cancer Institute of New Jersey on June 28.

In addition to a presentation of the new PhRMA report, the event featured a panel discussion of industry experts that was moderated by HINJ President and Chief Executive Officer Dean J. Paranicas.  The panelists were: Continue reading

U.S. House Subcommittee Defies Trump’s Budget and Proposes $1.1 Billion Boost for NHI

Washington, DC, July 13, 2017 — Rachel Roubein reports in The Hill that the U.S. House of Representatives subcommittee controlling the purse strings of the National Institutes of Health (NIH) on July 12 proposed a $1.1 billion boost for the agency, defying the Trump administration’s push for cuts.

The White House had proposed slashing the nation’s medical research agency by $5.8 billion.

But it was clear from the get-go that Congress wouldn’t support cutting NIH’s budget, with members of both parties in opposition. Continue reading

Poll Respondents Appreciate Innovation’s Economic, Social Benefits And Call For More Protections

Washington, DC, July 12, 2017Mark Grayson, deputy vice president of public affairs at the Pharmaceutical Research and Manufacturers of America (PhRMA), posts on the association’s blog, The Catalyst, that, increasingly, economists and international organizations are recognizing innovation as one of the most important drivers of economic and social progress and stability.

In fact, a report released earlier this year from the Global Intellectual Property Center, declared a robust innovation environment as “essential to the success of any 21st century economy.”

However, Grayson says it’s not just think tanks and academics acknowledging the value of innovation — the public is as well.  Continue reading

BIO Report Finds Bioscience Drives Economic Growth in States Across U.S.

Washington, DC, July 10, 2017 — A new report from Biotechnology Innovation Organization (BIO) concludes that the bioscience industry has had a positive impact on states’ economies and continues to be a driver of economic growth.

According to the new BIO report released in June, state lawmakers have recognized the importance of the industry, the authors state, and have responded to challenges facing the bioscience companies with legislative efforts focused on a supportive business climate. Continue reading

HINJ’s ‘Value of Medical Innovation’ Portal Showcases How Life Sciences Is Saving Money — And Lives

New Brunswick, NJ, July 9, 2017 ― The HealthCare Institute of New Jersey (HINJ) continues to update its Value of Medical Innovation, a fact-driven, consumer-friendly digital library that delves into the myriad benefits of research-driven medical innovation, which saves money — and saves lives.

Introduced in September 2015, HINJ’s Value of Medical Innovation presents statistics from a number of resources, including the Advanced Medical Technology Association (AdvaMed), the Biotechnology Innovation Organization (BIO), the Pharmaceutical Research and Manufacturers of America (PhRMA), U.S. government sources and various medical research organizations. Continue reading

NPR All Tech Considered: Before Silicon Valley, New Jersey Reigned as Nation’s Center of Innovation

Washington, DC, July 8, 2017Laura Sydell on June 5 reported on National Public Radio (NPR) on New Jersey’s history of innovation:

People from New Jersey are used to defending their state.

But, in fact, New Jersey has a history to brag about. Thomas Edison invented the light bulb, the phonograph and the movie camera there. Many decades later, Bell Labs invented the transistor in the state.

Geography favored New Jersey. On one end, it borders New York City, and on the other end is Philadelphia. That means easy access to Wall Street financing, transportation and industry headquarters. Continue reading